A Study Of PF-06263507 In Patients With Advanced Solid Tumors

Stopped early · Phase 1

Conditions studied: Neoplasms, Carcinoma, Non Small Cell Lung, Breast Neoplasms, Ovarian Neoplasms

In brief

To assess the safety and tolerability at increasing dose levels of PF-06263507 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.

Key facts

Study ID

NCT01891669

Run by

Pfizer

People needed

26

Starts

2013-08-08

Expected to finish

2015-06-29

Last updated by the study team

2019-01-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of solid tumor that is advanced/metastatic and resistant to standard therapy or for which no standard therapy is available.
• Performance Status of 0 or 1.
• Adequate bone marrow, kidney, liver, and heart function.

You may not qualify if…

• Brain metastases requiring steroids.
• Major surgery or anti-cancer therapy within 4 weeks of study treatment start.
• Active bacterial, fungal or viral infection.

Where it is running

• Brigham and Women's Hospital — Boston, Massachusetts, United States
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States
• Karmanos Cancer Institute — Detroit, Michigan, United States
• Fox Chase Cancer Center — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.